comparemela.com

Prnewswire Shanghai Henlius Biotech Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Henlius Deepens Collaboration with Intas to bring Henlius Novel anti-PD-1 mAb Serplulimab to Europe and India

/PRNewswire/ Shanghai Henlius Biotech, Inc. (2696.HK) has entered into an exclusive license agreement with Intas Pharmaceuticals Limited ("Intas") for the.

United kingdomUnited statesSouth africaAsia pacificFosun pharmaPaul tredwellJason zhuBinish chudgarPrnewswire shanghai henlius biotech incEuropean commissionIntas pharmaceuticals limitedAccord healthcare ltdJournal of the american medical associationDrug administrationEuropean medicines agencyIntas pharmaceuticals ltd

Henlius Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ESCC

/PRNewswire/ Shanghai Henlius Biotech, Inc. (2696. HK) announced that the new drug application (NDA) for new indication of HANSIZHUANG (serplulimab.

United statesUnited kingdomJing huangFosun pharmaWenjie zhangKalbe genexine biologics kgbioJason zhuCancer hospital chinese academy of medical sciencesEuropean commissionBureau of medical administrationEuropean medicines agencyCancer associationDrug administrationPrnewswire shanghai henlius biotech incJournal of the american medical associationJournal of the national cancer center

Henlius Expands Collaboration with KGbio to Develop, Commercialize and Supply Henlius novel anti-PD-1 mAb HANSIZHUANG in MENA

/PRNewswire/ Shanghai Henlius Biotech, Inc. (2696.HK) has entered into an exclusive license agreement with PT Kalbe Genexine Biologics ("KGbio"), an.

United statesSaudi arabiaUnited kingdomUnited arab emiratesKalbe farmaJason zhuKalbe genexine biologics kgbioNutritionals divisionPrescription pharmaceuticals divisionNational medicinal products administrationPrnewswire shanghai henlius biotech incConsumer health divisionDistribution logistics divisionEuropean unionIndonesia stock exchangeBusiness development of henlius

EMA Validates Marketing Authorization Application for Henlius HANSIZHUANG (Serplulimab)

/PRNewswire/ Shanghai Henlius Biotech, Inc. (2696.HK) announced that the European Medicines Agency (EMA) has validated the application for its.

United statesJason zhuPrnewswire shanghai henlius biotech incEuropean medicines agencyEuropean commissionEuropean unionHenlius biotechOrphan drug designation

Henlius Announces U S FDA Acceptance of Biologics License Application for Proposed Biosimilar Trastuzumab HLX02

/PRNewswire/ Shanghai Henlius Biotech, Inc. (2696.HK) announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License.

United statesUnited kingdomSaudi arabiaJason zhuPrnewswire shanghai henlius biotech incJacobson groupAccord biopharma incEuropean commissionDrug administrationIntas pharmaceuticals ltdEuropean medicines agencyNational medical products administrationHenlius biotechBiologics license applicationAccord biopharmaXuhui facility

vimarsana © 2020. All Rights Reserved.